Why ILMN fell 27% since Oct 29
Down 27% from Oct 29 to Nov 6 while the S&P 500 fell 4%.
“Illumina Crashes As Tariffs, AI Woes Eat Into 157% Run-Up.”
Down 27% from Oct 29 to Nov 6 while the S&P 500 fell 4%.
“Illumina Crashes As Tariffs, AI Woes Eat Into 157% Run-Up.”
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2022 high | Down 51% |
| Latest filing | 8-K, Oct 29 |
Tue Nov 10: UBS Global Healthcare Conference 2026Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed -5.5% on average, higher 1 of 4 times.
Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
ILMN is #6 of 15 by Quality Score among Laboratory Analytical Instruments.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 6 |
Share count against a year before: ILMN -3.8%, WAT +65%, TXG +5%, A -0.7%.
Expected to report Thu Feb 4, after the close (in 89 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $1.1B, 4% more than a year ago; a profit of $1.43 a share, from $0.98.
ILMN's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total revenue | $4.64B to $4.66B |
Sales grew 6% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 1.1% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 29, 2026 | -11.8% | -18.6% | -28.3% |
| Jul 30, 2026 | -0.9% | 0.0% | -5.5% |
| Apr 30, 2026 | +5.1% | +7.1% | +9.4% |
Sales grew in three of the last seven years, to $4.3B in 2025. It turned a profit in 2025 after a loss in 2024.
One insider sold $658M across 106 filings in the last 6 months. No open-market buys on record. The newest:
2 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ILMN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
ILMN scores 9 today, which Breakaway calls Average. It is #6 of 15 in Laboratory Analytical Instruments by Quality Score, with 1 of 14 chart checks firing. Down 27% from Oct 29 to Nov 6 while the S&P 500 fell 4%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ILMN scores 9 today, which Breakaway calls Average (6 to 10). That is #6 of 15 in Laboratory Analytical Instruments by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ILMN's 9.
One insider sold $658M across 106 filings in the last 6 months. No open-market buys on record. The newest is Keith A. Meister, Director, who sold $25.5M on Nov 3. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.